PMID- 37124282
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20231031
IS  - 1108-4189 (Print)
IS  - 1790-8019 (Electronic)
IS  - 1108-4189 (Linking)
VI  - 26
IP  - 1
DP  - 2022 Jan-Mar
TI  - The value of soluble suppression of tumorigenesis-2 (sST2) in the maintenance of 
      hemodialysis patients with heart failure.
PG  - 19-24
AB  - BACKGROUND: Patients with end-stage renal disease are prone to develop heart 
      failure (HF). The N-terminal pro-brain natriuretic peptide (NT-proBNP, BNP) is 
      regarded as the gold standard for diagnosing HF. However, its prognostic 
      sensitivity in patients with end-stage renal disease is sub-optimal. Soluble 
      suppression of tumorigenesis-2 (sST2) has been well studied in HF but rarely in 
      patients with maintenance hemodialysis (MHD). This study aimed to evaluate the 
      value of sST2 in predicting HF in MHD patients. METHODS: Twenty-three patients 
      with New York Heart Association (NYHA) class III-IV were included in the HF group 
      and 88 NYHA class I-II patients in the non-heart failure (NHF) group. sST2 and 
      laboratory indexes were compared between the two groups. RESULTS: The HF group, 
      compared with the NHF group, presented with higher sST2, more advanced age, 
      higher incidence of coronary heart disease (CHD), left ventricle end-diastolic 
      diameter (LVEDD), and pulmonary artery pressure (PAP), and unchanged parathyroid 
      hormone (iPTH). The HF group also had lower ejection fraction (EF), uric acid, 
      inorganic phosphorus, 25-OH VitD3, and serum albumin. Multivariate logistic 
      regression indicated that age, BNP, and sST2 were independent risk factors of HF 
      in MHD patients. Spearman analysis defined that sST2 was positively correlated 
      with PAP (r =0.283, p =0.003) and C-reactive protein (r =0.354, p <0.001); and 
      negatively correlated with sex (r =-0.255, p =0.007), albumin (r =-0.366, p 
      <0.001), uric acid (r =-0.213, p =0.025), 25-OH VitD3 (r =-0.216, p =0.04), 
      calcium (r =-0.219, p =0.021), and inorganic phosphorus (r =-0.256, p =0.007). 
      Receiver operating characteristic curve analysis determined a positive 
      association between BNP and sST2 (r =0.373, p <0.001), with the area under the 
      curve (AUC) of BNP being 0.822 (sensitivity: 0.783, specificity: 0.830) and the 
      AUC of sST2 being 0.841 (sensitivity: 0.913, specificity: 0.761). The AUC of sST2 
      was 0.841, and the cut-value was 42.840 (sensitivity: 0.913, specificity: 0.761). 
      CONCLUSION: sST2 can predict HF in MHD patients and facilitate early diagnosis 
      and prevention of HF in MHD patients. HIPPOKRATIA 2022, 26 (1):19-24.
CI  - Copyright 2022, Hippokratio General Hospital of Thessaloniki.
FAU - Zhou, X
AU  - Zhou X
AD  - Department of Nephrology, The First Affiliated Hospital of USTC, Division of Life 
      Sciences and Medicine, University of Science and Technology of China, Hefei, 
      Anhui, China.
FAU - Yi, F
AU  - Yi F
AD  - Department of Nephrology, The Lu'an Hospital Affiliated to Anhui Medical 
      University, The Lu'an People's Hospital, Lu'an, Anhui, China.
FAU - Peng, L
AU  - Peng L
AD  - Department of Nephrology, The First Affiliated Hospital of USTC, Division of Life 
      Sciences and Medicine, University of Science and Technology of China, Hefei, 
      Anhui, China.
FAU - Jiang, J
AU  - Jiang J
AD  - Department of Nephrology, The First Affiliated Hospital of USTC, Division of Life 
      Sciences and Medicine, University of Science and Technology of China, Hefei, 
      Anhui, China.
FAU - Lan, L
AU  - Lan L
AD  - Department of Nephrology, The First Affiliated Hospital of USTC, Division of Life 
      Sciences and Medicine, University of Science and Technology of China, Hefei, 
      Anhui, China.
LA  - eng
PT  - Journal Article
PL  - Greece
TA  - Hippokratia
JT  - Hippokratia
JID - 101296613
PMC - PMC10132390
OTO - NOTNLM
OT  - N-terminal pro-brain natriuretic peptide
OT  - NT-proBNP
OT  - Soluble suppression of tumorigenesis-2
OT  - heart failure
OT  - hemodialysis
OT  - sST2
COIS- Authors report no potential conflict of interest.
EDAT- 2022/01/01 00:00
MHDA- 2022/01/01 00:01
PMCR- 2022/01/01
CRDT- 2023/05/01 03:41
PHST- 2022/01/01 00:01 [medline]
PHST- 2022/01/01 00:00 [pubmed]
PHST- 2023/05/01 03:41 [entrez]
PHST- 2022/01/01 00:00 [pmc-release]
AID - 111540327 [pii]
PST - ppublish
SO  - Hippokratia. 2022 Jan-Mar;26(1):19-24.